• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

By: Pulmonx Corporation via GlobeNewswire
March 15, 2024 at 17:00 PM EDT

REDWOOD CITY, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today announced the inducement grant of equity awards to Steve Williamson, its newly-hired President and Chief Executive Officer, in accordance with Nasdaq Listing Rule 5635(c)(4).

On March 15, 2024, Pulmonx granted Mr. Williamson (i) 205,286 time-based restricted stock units, which will vest as to 25% of such units on March 3, 2025, with the remainder vesting in equal quarterly installments over the subsequent three-year period, and (ii) a nonstatutory stock option to purchase 425,116 shares of common stock with an exercise price of $8.95 per share, the closing price of Pulmonx's common stock on March 15, 2024, which will vest as to 25% of such shares on March 3, 2025, with the remainder vesting in equal monthly installments over the subsequent three-year period. The vesting of such awards is subject to Mr. Williamson’s continuous employment on each vesting date.

The equity awards to Mr. Williamson were granted as a material inducement to his employment, and were approved by Pulmonx’s board of directors in accordance with Nasdaq Listing Rule 5635(c)(4). The awards were granted outside of Pulmonx’s 2020 Equity Incentive Plan.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.pulmonx.com.

Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.

Investor Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com


Primary Logo

More News

View More
T-Mobile Earnings Show You Why This Is a Stock to Hold
Today 7:25 EDT
Via MarketBeat
Topics World Trade
Tickers TMUS
Bitcoin and Ethereum Surge: Here Are 5 Set to Ride the Wave
Today 7:06 EDT
Via MarketBeat
Topics ETFs
Tickers BMNR COIN ETHA IBIT
PEGA Surges 14%: There's Still Time to Ride This GenAI Innovator
July 27, 2025
Via MarketBeat
Topics Artificial Intelligence
Tickers FORR PEGA
Retail’s Comeback: 3 High-ROIC Stocks That Could Outshine AI
July 27, 2025
Via MarketBeat
Topics Artificial Intelligence Economy World Trade
Tickers AMZN BBWI BBY LULU
Homebuilding Headwinds Putting These 3 Stocks Under Pressure
July 27, 2025
Via MarketBeat
Topics Government Immigration World Trade
Tickers DHI KBH LEN NVR
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap